CDKN2A and cancer: HPV was detected in 80.4% of 163 tumors with strong, 62.3% of 42 tumors with moderate, 25.9% of 42 tumors with weak p16 positivity, but also in 20.6% of 250 p16 negative cancers (p<0.0001).